Determining the Prevalence of Muir-Torre Syndrome in Patients With Lynch Syndrome

Condition(s) studied

Investigational drug(s) / intervention(s)

Sampling of suspected skin lesions (in accordance with good care practices).: Sampling of suspected skin lesions (in accordance with good care practices) and swabbing of skin microbiota.

Constitution of a biobank: Collection of previously excised cutaneous and deep tumour lesions kept in a public or private pathological anatomy facility for these patients

Study summary

The main aim of this study is to determine the prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome (LS) confirmed by genetic analysis. Other aims include describing the dermatological clinical manifestations of these patients in order to describe any possible new cutaneous manifestations of this syndrome. Another aim is to use molecular biology (microsatellite instability) and immunohistochemistry to analyze non-sebaceous skin lesions and deep-seated tumors that do not belong to the narrow spectrum of Lynch syndrome, and determine whether their occurrence in these patients is related to the genetic syndrome. The follow-up of these tumors (screening for new tumors) in patients with SL, as recommended by the learned societies, will also be evaluated. Finally, a biobank of cutaneous and deep tumour lesions in paraffin (retrospective) and smears of cutaneous lesions and healthy tissue (prospective) will be set up.

Eligibility

Primary outcome measure(s)

• Prevalence of Muir-Torre syndrome (MTS) in the population of patients with Lynch syndrome — Up to 6 months after inclusion
  Proportion of patients with Muir-Torre Syndrome confirmed by the occurrence of a sebaceous tumor (sebaceous adenoma, sebaceoma, sebaceous carcinoma) or several keratoacanthomas among patients with Lynch Syndrome. These tumors may or may not have had the mismatch repair system analyzed by immunohistochemistry (analysis of the 4 antibodies MLH1, PMS2, MSH2, MSH6) or by molecular biology (search for microsatellite instability). If the mismatch repair system has been studied, it must be deficient and the proteins absent on immunohistochemistry must be consistent with the mutated gene in Lynch Syndrome. If a block or slides are still available, sebaceous skin tumors or keratoacanthomas will be re-evaluated at Nîmes University Hospital for confirmation of the diagnosis.

Trial sites (1)

More Centre Hospitalier Universitaire de Nīmes trials in France

Other trials for the same condition